Tiffany is the Vice President of Discovery at GentiBio. Prior to joining GentiBio, Tiffany was Director of Scientific Evaluation and Strategy and previously Director of Discovery at Rubius Therapeutics. As a starting scientist at Rubius, Tiffany developed the foundation of the company’s engineered red cell platform. She built out prototyping efforts for therapeutic candidates and platform capabilities by establishing the culture science and protein science teams that enabled preclinical activities in Discovery. As head of the Immunology Team, she led initial work in utilizing the red cell platform to address autoimmune diseases. Subsequently, Tiffany led efforts in the antigen specific immuno-oncology space and served as a cross-functional leader driving a program from early discovery through IND approval. Most recently, she led evaluation of external technologies and drove communications with external parties to lay the groundwork for future collaborations and partnerships. Tiffany is originally from Texas and holds a B.S. in Biomedical Engineering from the University of Texas at Austin and a Ph.D. in Biological Engineering from the Massachusetts Institute of Technology on engineering therapeutic proteins for immune modulation. In her spare time, Tiffany enjoys traveling, exploring places to eat, and being a doting dog aunt by spoiling the house dog with treats and pets.
Tiffany Chen, Ph.D.